Pro Medicus Limited (ASX: PME): Why the Surge in Share Price?

3 min read | September 10, 2024 02:13 PM AEST | By Team Kalkine Media

Google News:

Pro Medicus Limited (ASX: PME): Why the Surge in Share Price? — Image source: shutterstock

Recent News

Santos (ASX:STO) After the Takeover Collapse: Bargain or Value Trap?

Why Pro Medicus (ASX:PME) Is Leading the Growth Stock Conversation

Is 360 (ASX:360) Amid ASX 200 Revealing Growth’s New Reality?

Why 360 (ASX:360) ASX 200 Is Facing a New Growth Test

Make Kalkine Media
My Trusted Source

The Pro Medicus Limited (ASX:PME) share price has experienced a remarkable 63.6% increase since the beginning of 2024. This impressive rise in value highlights the growing interest in PME shares and raises the question of what is driving this surge. Additionally, an ASX healthcare stock is contributing to the broader sector's momentum.

Focus on Pro Medicus

Established in 1983, Pro Medicus is a leading provider of radiology IT software. The company offers a comprehensive suite of products designed to enhance medical imaging and diagnostic efficiency. Its core offerings include Radiology Information Systems (RIS), Picture Archiving and Communication Systems (PACS), and advanced visualization solutions.

A key component of Pro Medicus’s value proposition is its flagship Visage software. This platform enables radiologists to view and analyze large medical images remotely using mobile devices, facilitating timely and accurate diagnostic decisions and potentially improving patient outcomes.

Healthcare Sector Appeal

The healthcare sector, represented by the S&P/ASX200 Healthcare Index (ASX:XHJ), has outperformed other sectors with a return of 4.96% per year over the last five years, compared to the broader ASX average of 3.64%. Here are several reasons why healthcare companies, like Pro Medicus, are attracting attention:

- Stable Revenue: Healthcare is considered an essential service, often less affected by economic downturns. This stability in revenue makes healthcare companies a reliable investment, as demonstrated by the sector's resilience during the Global Financial Crisis (GFC).

- Growth Potential: The healthcare sector, particularly IT and data solutions, is experiencing rapid growth. In the US, which represents over 40% of global healthcare spending, profits are expected to increase by 7% annually from 2022 to 2027. The IT and 'software-as-a-service' (SaaS) segments within healthcare are projected to grow at more than 15% per year from 2024 to 2030.

- Ethical Investing: With a rising interest in sustainable and ethical investing, healthcare companies that provide crucial public services are well-positioned to attract investors focusing on social impact.

Valuation Insights

Pro Medicus shares are currently trading at a price-to-sales ratio of 101.93x, which is above its 5-year average of 85.76x. This indicates that PME shares are priced higher than their historical average. However, it's important to consider multiple factors and valuation methods when evaluating investment opportunities.

The impressive performance of Pro Medicus Limited highlights the growing investor confidence in the healthcare sector, driven by the company's innovative solutions and the sector's overall growth potential.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.